クローナルネオアンチゲンはT細胞の免疫反応と免疫チェックポイントの阻害に対する感受性を誘発する
Nicholas McGranahan1, Andrew J S Furness2, Rachel Rosenthal3
1The Francis Crick Institute, London WC2A 3LY, UK. Centre for Mathematics and Physics in the Life Sciences and Experimental Biology (CoMPLEX), University College London (UCL), London WC1E 6BT, UK. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK.
まとめ
腫瘍新抗原の異質性は免疫反応に影響する. 肺がんやメラノーマの免疫チェックポイント阻害剤の有効性を改善する可能性がある.
科学分野:
- 腫瘍学
- 免疫学
- 遺伝学
背景:
- 腫瘍は変異を蓄積し 免疫チェックポイント阻害剤への反応に影響する新抗原を生成します
- 腫瘍内新抗原の異質性 (ITH) は,抗腫瘍免疫において重要な役割を果たします.
研究 の 目的:
- 抗腫瘍免疫に対するネオアンチゲンITHの影響を調査する.
- ネオアンチゲン負荷と患者の生存率の関係を探るため
主な方法:
- ITHとネオアンチゲン負荷の統合分析
- ネオアンチゲンに反応するCD8 ((+) 腫瘍浸透性リンパ球の特定.
- PD-1とCTLA-4の阻害に対する患者の反応の分析
主要な成果:
- クローン新抗原負荷は肺腺がんにおける全生存率と相関する.
- CD8 ((+) クローン新抗原を標的にするT細胞はPD-1を発現し,初期段階の非小細胞肺がんに見られる.
- クローン新抗原を持つ腫瘍は,進行NSCLCおよびメラノーマにおいてPD- 1/ CTLA- 4阻害に対する感受性が高まっている.
- 化学療法によるサブクローナルネオアンチゲンは,一部の患者で不十分な反応と関連しています.
結論:
- ネオアンチゲンの異質性は免疫監視に影響する.
- 免疫チェックポイントの封鎖に対する 治療的可能性を示しています
関連する概念動画
T Cell Activation and Clonal Selection
17.2K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
17.2K
Tumor Immunotherapy
2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Cytotoxic T Cells-mediated Immune Response
7.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.9K
Cells of the Adaptive Immune Response
10.0K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
10.0K
Cell-mediated Immune Responses
86.0K
Overview
86.0K
Antigens Involved in Adaptive Immunity
1.8K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K


